echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first single-dose option for pediatric ABSSSI!

    The first single-dose option for pediatric ABSSSI!

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, AbbVie announced that the FDA approved Dalvance for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients (from birth to under 18)


    ABSSSI is a bacterial infection of the skin and related tissues, mainly caused by Gram-positive bacteria, including Staphylococcus aureus (methicillin-sensitive and resistant strains, etc.


    Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that inhibits the synthesis of bacterial cell walls


    The FDA approval is based on the results of a multi-center, open-label, positive-controlled clinical trial and 3 pharmacokinetic studies to evaluate the safety and effectiveness of dalbavancin in pediatric patients


    To evaluate the therapeutic effect of dalbavancin, 183 patients with ABSSSI in the modified intention-to-treat (mITT) population were analyzed


    At present, a total of 7 new drugs for the treatment of ABSSSI have been approved for marketing worldwide, one is in the application for listing stage, and one is in the phase III clinical stage


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.